First-in-human dose escalation and expansion study of SYSA1801, an antibody-drug conjugate targeting claudin 18.2 in patients with resistant/refractory solid tumors.
Yakun Wang(Peking University), Lin Shen(Peking University), Dan Su(Harbin Medical University), Qianli Wang(BGI Group (China)), Shen Zhao(Fujian Provincial Cancer Hospital), Ying Chen(Hunan University of Traditional Chinese Medicine), Yang Yang(CSPC Pharmaceutical Group), Ling Lin(Haikou City People's Hospital), Jingdong Zhang(Liaoning Cancer Hospital & Institute), Qian Dong(Liaoning Cancer Hospital & Institute), Jufeng Wang(Henan Cancer Hospital), Xuechao Wan(CSPC Pharmaceutical Group), Wen Tian(Haikou City People's Hospital), Xueyuan Zhang(CSPC Pharmaceutical Group), Yanqiao Zhang(Harbin Medical University), Jinfeng Gao(CSPC Pharmaceutical Group), Na An(Chinese Academy of Medical Sciences & Peking Union Medical College), Rongbo Lin(Fujian Provincial Cancer Hospital), Jifang Gong(Peking University), Valerie M. Jansen(New York Oncology Hematology)
Cited by 32
Related Papers
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021
|Cancer Communications|2021|657
Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial
|Nature Medicine|2023|541
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission
|New England Journal of Medicine|2020|432